Triheptanoin FDA approval date

The FDA approved Triheptanoin (Dojolvi) on 30 Jun 2020.

FDA approval date
30 Jun 2020

Drug identity checked against registry records

Also recorded as Dojolvi; UX007

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODNCT05933200RAREPhase 3Active not recruiting2027-08Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2020-06-30DayTriheptanoinFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA213687", "applicant_as_listed_by_fda": "ULTRAGENYX PHARM INC", "brand_names": ["DOJOLVI"], "active_ingredients": ["TRIHEPTANOIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20200630", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026